Imidazopiperazine inhibitors of transcription activating proteins

Patent metadata

Field	Value
Publication number	US-12186324-B2
Application number	US-202117327217-A
Country	US
Kind code	B2
Filing date	May 21, 2021
Priority date	Mar 29, 2018
Publication date	Jan 7, 2025
Grant date	Jan 7, 2025

Abstract

The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.

First claim

What is claimed is:

1. A compound of structural Formula III

or a salt thereof, wherein:
R 1 is chosen from alkyl, cycloalkyl and heterocycloalkyl;
R 2 is chosen from —CH 3 , —CH 2 F, —NH 2 , —NHCH 3 , and —OCH 3 ;
R 4a and R 4b are H;
W is chosen from C(R 7a ) and N;
X 1 is independently chosen from C(R 7b ) and N;
X 2 and X 3 are independently chosen from C(H) and N;
Y and Z are independently chosen from C(H) and N;
R 7a is chosen from H, alkyl, alkoxy, cyano, carboxy, halo, haloalkyl, hydroxy, and OXO;
R 7b is chosen from H and fluoro;
R 8 is chosen from aryl, heteroaryl, and heterocycloalkyl, and is optionally substituted with 1, 2, or 3 R 10 groups; and
each R 10 is independently chosen from alkyl, cyclopropyl, methoxy, cyano, halo, difluoromethyl, trifluoromethyl, trifluoromethoxy, hydroxy, CONH 2 , and CONHCH 3 .

2. The compound as recited in claim 1 , or a salt thereof, wherein:
X 1 is C(R 7b );
X 2 and X 3 are C(H); and
Z is C(H).

3. The compound as recited in claim 2 , or a salt thereof, wherein R 8 is a monocyclic aryl or heteroaryl, and is optionally substituted with 1 or 2 R 10 groups.

4. The compound as recited in claim 3 , or a salt thereof, wherein each R 10 is independently chosen from alkyl, cyclopropyl, methoxy, cyano, halo, difluoromethyl, trifluoromethyl, trifluoromethoxy, hydroxy, CONH 2 , and CONHCH 3 .

5. The compound as recited in claim 4 , or a salt thereof, wherein R 8 is 5-membered monocyclic heteroaryl, and is optionally substituted with 1 or 2 R 10 groups.

6. The compound as recited in claim 5 , or a salt thereof, wherein R 7a is H.

7. The compound as recited in claim 6 , or a salt thereof, wherein R 7b is H.

8. The compound as recited in claim 7 , or a salt thereof, wherein R 1 is chosen from:
—CH 3 , —CH(CH 3 ) 2 ,

9. The compound as recited in claim 8 , or a salt thereof, wherein R 8 is chosen from pyrrolyl, isoxazolyl, thiazolyl, imidazolyl, and pyrazolyl, any of which is optionally substituted with 1 or 2 R 10 groups.

10. The compound as recited in claim 9 , or a salt thereof, wherein R 8 is substituted with 1 R 10 group.

11. The compound as recited in claim 10 , or a salt thereof, wherein R 8 is

12. The compound as recited in claim 11 , or a salt thereof, wherein R 10 is alkyl.

13. The compound as recited in claim 12 , or a salt thereof, wherein R 10 is methyl.

14. The compound as recited in claim 12 , or a salt thereof, wherein:
W is N; and
Y is C(H).

15. The compound as recited in claim 14 , or a salt thereof, wherein R 10 is methyl.

16. The compound as recited in claim 12 , or a salt thereof, wherein:
W is C(R 7a ); and
Y is N.

17. The compound as recited in claim 16 , wherein R 7a is haloalkyl.

18. The compound as recited in claim 16 , or a salt thereof, wherein R 10 is methyl.

19. The compound as recited in claim 14 , wherein R 2 is —CH 3 .

20. The compound as recited in claim 16 , wherein R 2 is —NHCH 3 .

21. A method of treatment of a cancer chosen from acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, acute T-cell leukemia, breast cancer, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, chronic myelogenous leukemia, diffuse large B-cell lymphoma, erythroleukemia, estrogen-receptor positive breast cancer, leukemia, lung cancer, lymphoblastic leukemia, lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, multiple myeloma, myelogenous leukemia, myeloma, non-small cell lung cancer, ovarian cancer, prostate cancer, renal cell carcinoma, and small cell lung cancer, comprising the administration of a therapeutically effective amount of a compound as recited in claim 1 to a patient in need thereof, wherein the treatment comprises the prevention of progression of the disease to a later stage.

22. The method as recited in claim 21 , wherein said cancer is chosen from lung cancer, breast cancer, and melanoma.

23. The method as recited in claim 21 , further comprising the administration of a cytotoxic agent.

24. The method as recited in claim 23 , wherein said cytotoxic agent is chosen from anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormonal analogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents, proapoptotic agents, inhibitors of LDH-A, inhibitors of fatty acid biosynthesis, cell cycle signaling inhibitors, HDAC inhibitors, proteasome inhibitors, and inhibitors of cancer metabolism.

25. The method as recited in claim 21 , further comprising the administration of a non-chemical method of cancer treatment.

26. The method as recited in claim 25 , wherein said non-chemical method of cancer treatment is chosen from surgery, radiation therapy, thermoablation, focused ultrasound therapy, and cryotherapy.

Assignees

• Univ Texas

Inventors

• Le Kang
• Soth Michael J
• Jones Philip
• Cross Jason Bryant
• Carroll Christopher L
• Mcafoos Timothy Joseph
• Mandal Pijus Kumar

Classifications

• C07D471/04

  Ortho-condensed systems · CPC title

• C07D495/04

  Ortho-condensed systems · CPC title

• A61K31/4985 Primary

  Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems · CPC title

• C07D487/04 Primary

  Ortho-condensed systems · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title